Bio-Thera's BAT2206 ustekinumab candidate is in contention with multiple other proposed biosimilars to Janssen's Stelara.
Ustekinumab (Stelara) is a blockbuster drug for the treatment of Crohn disease, ulcerative colitis, and psoriatic arthritis that brought in $5.24 billion in revenues for Janssen Pharmaceuticals in 2020, up from $4.35 billion in 2019. There are many contenders in the global race to produce the first biosimilar for this product, and progress reports are now routine.
This week, Bio-Thera Solutions of Guangzhou, China, said it has dosed the first patient in a phase 3 clinical trial of a biosimilar candidate for ustekinumab (BAT2206). Phase 3 trials, if successful, typically precede a regulatory filing for marketing approval.
Bio-Thera is a commercial-stage pharmaceutical company—it has 1 product in circulation, an adalimumab biosimilar (Qletli), which became available on the Chinese market in January 2020. Besides BAT2206, Bio-Thera has several biosimilar candidates in clinical stages of development, including BAT1806, a tocilizumab biosimilar candidate, and BAT2506, a golimumab biosimilar candidate.
Tocilizumab (Actemra) is used in the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, systemic sclerosis–associated interstitial lung disease, and giant cell arthritis. Bio-Thera said its tocilizumab candidate has successfully completed a global phase 3 clinical trial.
Golimumab (Simponi) is used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. BAT1806 and BAT2506 have each entered the phase 3 trial stage, according to Bio-Thera.
Bio-Thera’s ustekinumab candidate is undergoing evaluation in a multicenter, randomized, double-blind, controlled study (N = 472) comparing the efficacy and safety of BAT2206 with the reference product in patients with moderate-to-severe psoriatic arthritis.
Ustekinumab works by suppressing the action of cytokines interleukin (IL)-12 and IL-23, which facilitate immune cell signaling and in disorders that involve an overstimulated immune system response. “IL-12 and IL-23 have been implicated as important contributors to the chronic inflammation that is a hallmark of Crohn disease and ulcerative colitis, among many other autoimmune diseases,” Bio-Thera said in its statement.
Also, the company has a bevacizumab biosimilar candidate that has completed phase 3 clinical trial development. In April, Bio-Thera reported it has entered a commercialization agreement with Biogen for the distribution of the tocilizumab biosimilar candidate in countries outside the China region.
Other companies in the ustekinumab biosimilar development race include NeuClone of Sydney, Australia (NeuLara), Samsung Bioepis (SB17), Formycon and Bioeq (FYB202), Amgen (ABP 654), Meiji Seika (DMB-3115), and Celltrion (CT-P43).
The Growing Impact of Biosimilars in IBD Care
April 23rd 2025Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.